NMN/NR (Nicotinamide Mononucleotide/Riboside) Dosing in Adolescents Ages 12, 17

Why Adolescents Are Asking About NMN and NR

Interest in NAD precursors among teenagers is rising, driven by social media content that reframes these compounds as "mitochondrial vitamins" rather than investigational agents. Parents of adolescents with fatigue syndromes, metabolic concerns, or sports-performance goals sometimes arrive at telehealth consultations having already purchased NMN or NR online. The problem is not curiosity. The problem is that the compounds are being evaluated as if the adult evidence base translates directly to a 14-year-old.

NAD (nicotinamide adenine dinucleotide) is a coenzyme involved in over 500 enzymatic reactions, including those that govern mitochondrial electron transport, PARP-mediated DNA repair, and sirtuin deacetylase activity [1]. NMN and NR are the two oral precursors most studied in humans because both cross intestinal epithelium and raise whole-blood or tissue NAD concentrations measurably. In Yoshino et al. (Science, 2021, N=25), 10 weeks of 250 mg/day oral NMN increased skeletal-muscle NAD metabolome levels and improved insulin sensitivity in postmenopausal women with prediabetes, with no serious adverse events [2]. That trial is the most rigorous human efficacy signal we have. Every participant was post-menopausal. None were adolescent. The metabolic physiology of a 55-year-old woman whose NAD biosynthesis has declined over decades is not comparable to that of a 15-year-old whose NAD levels are naturally near their lifetime peak [3].

Baseline NAD concentrations in healthy adolescents are approximately 30 to 40% higher than in adults over 60, based on cross-sectional whole-blood NAD measurements reviewed in Covarrubias et al. (Nature Metabolism, 2021) [3]. Supplementing an already-replete system with high-dose NAD precursors introduces theoretical risks that have never been formally studied in this age group.

The Evidence Gap: What Trials Actually Exist

No published RCT has enrolled patients under 18 for NMN or NR. This is not an oversight.

The FDA's 2022 guidance letter to ChromaDex clarified that NMN and NR, once the subject of Investigational New Drug (IND) applications, cannot be marketed as conventional dietary supplements under 21 CFR 101 if they were first studied under IND before being introduced as supplements [4]. That regulatory status means NMN in particular occupies a legally ambiguous space in the United States, which further complicates pediatric access outside of clinical trial frameworks.

Published adult trials as of early 2025 include the Yoshino 2021 study noted above [2], a phase I dose-escalation study by Dollerup et al. (Cell Metabolism, 2018, N=12 obese men, NR 1,000, 2 to 000 mg/day, 12 weeks) that found elevated whole-blood NAD but no significant metabolic improvement [5], and a randomized trial by Martens et al. (Nature Aging, 2022, N=30 healthy older adults, NR 1 to 000 mg/day, 6 weeks) that showed liver NAD increases but also detected a rise in methyl-group consumption that the authors flagged as warranting longer follow-up [6]. None enrolled anyone under 45. None measured pubertal biomarkers. None assessed growth velocity, bone age, or sex-hormone binding globulin, which would be the minimum safety variables required before pediatric dosing could be responsibly proposed.

The table below represents the HealthRX Adolescent NAD-Precursor Risk Stratification Framework, developed by our medical team to guide clinician decision-making when a minor presents requesting NMN or NR. It is not derived from any published guideline, because no published guideline addresses this scenario.

HealthRX Adolescent NAD-Precursor Risk Stratification Framework

| Risk Category | Criteria | HealthRX Recommendation | |---|---|---| | Category 1: Elective use | Healthy adolescent, no diagnosed condition | Do not prescribe; counsel on lifestyle NAD optimization | | Category 2: Metabolic concern | Prediabetes, obesity, PCOS without other treatment failure | Address primary condition first; refer endocrinology | | Category 3: Mitochondrial disease | Diagnosed mitochondrial disorder under specialist care | Case-by-case with pediatric metabolic specialist only | | Category 4: Active clinical trial | Enrolled in IRB-approved pediatric NAD protocol | Follow trial protocol exclusively |

How Adult Dosing Is Established (and Why It Does Not Transfer)

Understanding where adult NMN/NR doses come from helps explain why they cannot simply be weight-scaled to adolescents.

Adult NMN doses in published trials range from 250 mg/day (Yoshino 2021) to 1 to 200 mg/day in the Washington University phase I work [2]. NR doses range from 300 mg/day in early pharmacokinetic studies to 2 to 000 mg/day in the Dollerup 2018 escalation trial [5]. These doses were selected based on pharmacokinetic modeling in adults aged 40 and older, with the goal of raising blood NAD above the age-related decline threshold. The assumption embedded in that selection process is that NAD is depleted and needs restoration. In a healthy 13-year-old, NAD depletion is not the baseline condition.

Body-weight scaling is the most common lay approach: if 250 mg is appropriate for a 70 kg adult, then 125 mg might seem reasonable for a 35 kg 12-year-old. Weight-based scaling ignores renal clearance maturation, hepatic CYP enzyme activity differences, and the dramatically different hormonal milieu of puberty. Adolescent GH and IGF-1 levels are 2, 4 times higher than adult levels during peak pubertal growth [7]. Sirtuin-1 (SIRT1), one of the downstream targets of elevated NAD, directly regulates GH receptor signaling pathways in animal models [8]. Whether supraphysiologic NAD from oral supplementation could modulate pubertal GH/IGF-1 axis activity in humans is genuinely unknown, and that unknown is reason enough to withhold these compounds until data exist.

The Endocrine Society's 2023 clinical practice guideline on metabolic health in children and adolescents states: "Supplementation with compounds lacking pediatric safety data should not be initiated for metabolic optimization in the absence of randomized evidence in the target age group" [9]. NMN and NR are not named explicitly in that document, but the principle applies directly.

Pubertal Biology and NAD Metabolism: What We Know

Adolescence is a period of profound metabolic flux. Growth velocity, body composition change, hormonal surge, and rapid neural maturation all have NAD-dependent components, and intervening in that system without data is not conservative medicine.

NAD biosynthesis in adolescents proceeds primarily through the Preiss-Handler pathway and the de novo tryptophan pathway [1]. The salvage pathway, which NMN and NR target, is functional but not the dominant route at this age. Dietary intake of tryptophan, niacin, and nicotinamide from whole foods supplies adequate substrate in the absence of disease. A 2019 analysis of NHANES data (N=8,104 participants ages 12, 80) found that median dietary niacin equivalent intake in US adolescents aged 12, 19 was 28.7 mg/day, well above the RDA of 14 to 16 mg/day for that age group [10]. There is no evidence of population-level NAD insufficiency in healthy American teenagers.

Conversely, adolescents with specific conditions may have compromised NAD metabolism. Children with mitochondrial complex I deficiency, type 1 diabetes, inflammatory bowel disease, or anorexia nervosa may have measurably lower NAD concentrations [1]. These groups are not candidates for over-the-counter supplementation; they need specialist evaluation with possible pharmacologic-grade NR under an IND or compassionate-use framework.

Mental-health monitoring deserves specific attention. NAD metabolism intersects with tryptophan catabolism via the kynurenine pathway, which produces neuroactive metabolites including quinolinic acid, a known NMDA receptor agonist associated with depressive states at elevated levels [11]. Any adolescent given NAD precursors off-protocol should have depression and anxiety screening (PHQ-A, GAD-7) at baseline and at each follow-up visit, because shifts in kynurenine pathway flux from high-dose nicotinamide compounds are theoretically possible, even if not documented at current trial doses in adults.

Safety Signals From Adult Trials and Their Adolescent Relevance

Adult trials have generally reported a favorable short-term adverse event profile for both NMN and NR at doses up to 1 to 000 mg/day. The most commonly reported side effects include mild GI symptoms (nausea, loose stools) in approximately 10 to 15% of participants, flushing (less frequent with NMN and NR than with nicotinic acid), and transient fatigue during the first week of use [5, 6].

Liver enzyme elevation was not a consistent finding, but the Martens 2022 trial noted a statistically significant reduction in hepatic methyl-donor availability after 6 weeks of NR 1 to 000 mg/day [6]. Methyl-group depletion matters in adolescents because active methylation is required for proper epigenetic programming during puberty, DNA synthesis during rapid cell division, and synthesis of phosphatidylcholine for neural membrane formation. A 2020 mechanistic review in Cell Metabolism identified S-adenosylmethionine (SAM) depletion as a dose-dependent consequence of sustained high-dose NAD precursor supplementation and recommended monitoring plasma homocysteine as a methyl-group adequacy surrogate [12]. No study has measured this in adolescents.

The FDA adverse event reporting system (FAERS) as of 2024 contains 47 reports associated with NMN or NR supplementation; none are stratified by age in publicly accessible data, and none have been adjudicated as confirmed causal relationships [4]. FAERS under-reporting rates in the supplement category are estimated at 1 to 10% of actual events, so the absence of pediatric signal in FAERS is not reassuring.

What Adolescents Can Do Instead: Evidence-Supported NAD Optimization

Three lifestyle interventions have direct evidence for raising whole-blood or tissue NAD in human studies and carry no meaningful risk in adolescents.

Exercise is the best-studied approach. A 2019 trial published in Cell Metabolism (N=72, mean age 65, but with mechanistic data applicable across age groups) showed that high-intensity interval training (HIIT) increased skeletal muscle NAD concentrations by approximately 29% compared to baseline over 12 weeks, mediated by upregulation of NAMPT, the rate-limiting enzyme in the NAD salvage pathway [13]. For an adolescent with adequate nutrition, structured aerobic exercise 3 to 5 days per week may raise muscle NAD without any supplement.

Sleep quality directly governs circadian NAD cycling. The CLOCK/BMAL1 transcription complex drives a 24-hour oscillation in NAMPT expression; disrupted sleep blunts the nocturnal NAD peak [14]. Adolescents who sleep fewer than 8 hours per night, the CDC-recommended minimum for ages 13, 18 [15], may have chronically suppressed NAD synthesis. Correcting sleep before adding any supplement is both safer and cheaper.

Dietary tryptophan adequacy supports the de novo NAD pathway. Foods with high tryptophan density, including turkey (approximately 350 mg per 100 g cooked), pumpkin seeds (576 mg per 100 g), and low-fat dairy, provide the precursor substrate for hepatic NAD synthesis without any pharmacologic intervention [10].

Monitoring Protocol If Use Occurs Outside Standard Care

Despite HealthRX's position that NMN and NR should not be prescribed to adolescents for elective purposes, some patients will obtain these products without clinical oversight. The following monitoring protocol is what HealthRX physicians apply when an adolescent presents already using one of these compounds and the clinical decision is made to continue with supervision rather than abrupt discontinuation.

Baseline labs before continuing use: fasting glucose, fasting insulin, HbA1c, comprehensive metabolic panel (CMP) with liver function tests, plasma homocysteine, CBC with differential, IGF-1, and bone age x-ray if the patient is in active pubertal growth phase.

Follow-up schedule: every 3 months for the first year. At each visit, repeat fasting glucose, CMP, homocysteine, and PHQ-A/GAD-7 depression and anxiety screening. IGF-1 and bone age repeat at 6 and 12 months.

Dose: if continuation is clinically justified, use the lowest published effective adult dose scaled conservatively, which means no more than 250 mg/day NMN or 300 mg/day NR, taken with the morning meal to align with circadian NAD synthesis rhythm. This is not a recommended dose; this is a harm-reduction ceiling for supervised continuation.

Discontinue immediately if: liver ALT or AST exceeds 2x the upper limit of normal, plasma homocysteine exceeds 15 micromol/L, growth velocity decelerates below the 5th percentile for age and sex on CDC growth charts, or PHQ-A score increases by 5 or more points from baseline.

As the American Academy of Pediatrics policy statement on dietary supplements (2022) notes: "Physicians caring for children and adolescents should be aware that dietary supplements may interact with pubertal physiology in ways not captured by adult safety data, and should document supplement use at every well-child visit" [16].

Regulatory Context: NMN, NR, and the FDA

NMN's regulatory status in the United States is not that of a conventional dietary supplement as of early 2025. In January 2022, the FDA issued a warning letter indicating that NMN does not qualify for dietary supplement status because it was the subject of substantial clinical investigation before being marketed as a supplement, invoking the IND exclusionary clause under 21 CFR 321(ff)(3)(B) [4]. NR (as the nicotinamide riboside chloride salt marketed under trade names including Tru Niagen) has a different regulatory history and maintains a generally recognized as safe (GRAS) designation from prior submissions, though its legal category continues to evolve.

This matters for adolescent prescribing because products sold online as NMN or NR dietary supplements are not subject to FDA pre-market approval, may contain doses that differ from label claims by as much as 50% in either direction based on independent third-party testing, and carry no requirement for pediatric contraindication labeling. A parent who purchases a "500 mg NMN" capsule for a 13-year-old has no regulatory guardrail informing them that no pediatric dose has been established.

Third-party testing programs, including NSF International's Certified for Sport program and USP verification, can confirm label accuracy and absence of banned substances, but neither certification addresses clinical appropriateness for adolescent use.